Systemic lupus erythematosus. N Engl J Med

Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom.
New England Journal of Medicine (Impact Factor: 55.87). 03/2008; 358(9):929-39. DOI: 10.1056/NEJMra071297
Source: PubMed


Pathogenic autoantibodies are the primary cause of tissue damage in patients with lupus. The production of these antibodies arises by means of complex mechanisms involving every key facet of the immune system. Many different elements of the system are potential targets for therapeutic drugs in patients with lupus.

1 Follower
11 Reads
  • Source
    • "Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can affect any part of the body. SLE occurs more often in women than men (59). This disease may be the result of an attack by the immune system on cells and tissues of the body that occurs by producing antibodies against itself. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stem cell therapy is a powerful technique for the treatment of a number of diseases. Stem cells are derived from different tissue sources, the most important of which are the bone marrow (BM), umbilical cord (UC) blood and liver. Human UC mesenchymal stem cells (hUC-MSCs) are multipotent, non-hematopoietic stem cells that have the ability to self-renew and differentiate into other cells and tissues such as osteoblasts, adipocytes and chondroblasts. In a number of reports, human and mouse models of disease have hUC-MSCs treatments. In this article, we review studies that pertain to the use of hUC-MSCs as treatment for diseases.
    Cell Journal 12/2014; 15(4):274-281. · 1.11 Impact Factor
  • Source
    • "It can lead to enhanced processing and presentation of selfantigens, which induces the expansion or spreading of immune response toward different selfantigens (Gershwin 2008; Sfriso et al. 2010). SLE is a multifactorial systemic autoimmune disorder which affects multiple organs including the skin, lung, joints, kidneys, and heart (Rahman and Isenberg 2008). The cause of SLE is unknown, however many abnormalities in cellular and humoral immune responses including autoantibody production by dysregulated B cells, aberrant immune cell activation due to abnormal antigen presenting cells (APC) function, and autoantigen production have been reported in SLE patients (Steinberg 1992; Wozniacka et al. 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although many patients with SLE also have allergies, the immunological events triggering the onset and progression of the clinical manifestations of SLE by allergens have yet to be clarified. A total of three autoantigens, phosphoglycerate kinase 1 (PGK-1), triosephosphate isomerase (TIM) and enolase were identified by autologous serum in B cell lysate derived from HDM allergic SLE patients after Der p 2 stimulation. Autoantigen, TRIM-21 expression were also significantly increased in B cells derived from HDM allergic SLE patients. In PBMCs derived from SLE patients, the concentration of anti-PGK-1 was significantly upregulated after Der p 2 stimulation compared to HDM allergic without SLE patients and healthy subjects. Inflammatory related cytokines and chemokines include IL-1β, IL-6, IL-8, CXCL5 could be upregulated after Der p 2 stimulation in PBMCs derived from HDM allergic SLE patients. In conclusion, our data demonstrated that long-term allergen exposure could be a contributing factor in the development of SLE.
    Immunobiology 08/2014; 219(12). DOI:10.1016/j.imbio.2014.07.018 · 3.04 Impact Factor
  • Source
    • "Systemic lupus erythematosus (SLE) is an autoimmune disease that leads to progressive end-organ damage and is characterized by the presence of autoantibodies directed against nuclear and cytoplasmic antigens [1] [2] [3]. Globally, the incidence rate of SLE varies from 1 to 10 per 100,000 person-years and the prevalence rate varies from 20 to 70 per 100,000 person-years [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Macrophage migration inhibitory factor (MIF) is an upstream immunoregulatory cytokine associated with the pathogenesis of autoimmune inflammatory diseases. There is evidence that MIF functions in a positive feedback loop with TNF-α that could perpetuate the inflammatory process in systemic lupus erythematosus (SLE). In this case-control study we investigated whether commonly occurring functional MIF polymorphisms are associated with SLE as well as with MIF and TNF- α serum levels in a Mexican-Mestizo population. Genotyping of the -794CATT5-8(rs5844572) and -173G>C(rs755622) MIF polymorphisms was performed by PCR and PCR-RFLP respectively in186 SLE patients and 200 healthy subjects. MIF and TNF- α serum levels were determined by ELISA. A significant increase of MIF and TNF- α levels was found in SLE patients. According to a genetic model, we found a significant association of genotypes carrying the -794CATT7 and -173∗C risk alleles with susceptibility to SLE and with a significant increase of TNF-α. In conclusion, MIF gene polymorphisms are associated with SLE susceptibility and with an increase of TNF-α serum levels in a Mexican-Mestizo population.
    Human immunology 05/2014; 75(5). DOI:10.1016/j.humimm.2014.02.014 · 2.14 Impact Factor
Show more